Compare LYTS & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYTS | IRWD |
|---|---|---|
| Founded | 1976 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 698.9M | 663.6M |
| IPO Year | 1994 | 2009 |
| Metric | LYTS | IRWD |
|---|---|---|
| Price | $23.07 | $3.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $27.50 | $7.67 |
| AVG Volume (30 Days) | 490.9K | ★ 2.5M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | ★ 0.48 | 0.24 |
| Revenue | ★ $573,377,000.00 | $298,276,000.00 |
| Revenue This Year | $16.20 | $57.95 |
| Revenue Next Year | $27.71 | $4.39 |
| P/E Ratio | $46.94 | ★ $16.10 |
| Revenue Growth | ★ 22.09 | 8.88 |
| 52 Week Low | $15.62 | $0.56 |
| 52 Week High | $24.99 | $5.78 |
| Indicator | LYTS | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 49.39 |
| Support Level | $21.76 | $3.80 |
| Resistance Level | $23.84 | $3.92 |
| Average True Range (ATR) | 0.76 | 0.29 |
| MACD | -0.28 | -0.05 |
| Stochastic Oscillator | 37.79 | 34.25 |
LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.